Publications by authors named "L M Mitrofan"

Objective: Several studies in the specialized literature have reported that events such as the death of a loved one, job loss, divorce, illness, or retirement lead to an increase in the level of stress felt, and subsequently stress affects the person on several levels of life, such as: personal, relational, social, academic and at the same time sanogenic. The present paper explored the relationship between critical life events and psycho-emotional health among youths and the manner in which this relationship is mediated by the level of life satisfaction.

Methods: The data was extracted using a sample of participants (between 20 and 40 years old) from several cities in Romania, who experienced one or more critical life events during the last year.

View Article and Find Full Text PDF

Background: The Inventory of Depression and Anxiety Symptoms (IDAS-II) is a self-report measure comprising 99 items divided into 18 non-overlapping scales that allows for a dimensional assessment of depression, anxiety, and bipolar symptoms. The IDAS-II is currently available in English, Turkish, Spanish, German, and Swedish. This study's major goal was to adapt and validate the IDAS-II to the Romanian population.

View Article and Find Full Text PDF

Background: Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting.

Methods: A retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe.

View Article and Find Full Text PDF

Several pre-clinical and clinical studies have demonstrated zoledronic acid (Zol), which regulates the mevalonate pathway, has efficient anti-cancer effects. Zol can also induce autophagy. The aim of this study is to add new understanding to the mechanism of autophagy induction by Zol.

View Article and Find Full Text PDF

Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient survival. In this study, we investigated in vivo the effects of RAD001 (Everolimus), a new orally available mTOR inhibitor, on the growth of human and mouse osteosarcoma cells either alone or in combination with zoledronate (ZOL), an anti-osteoporotic drug used to treat bone metastases. RAD001 inhibited osteosarcoma cell proliferation in a dose- and time-dependent manner with no modification of cell-cycle distribution.

View Article and Find Full Text PDF